Search

A 59-year-old woman developed kidney granulomas while undergoing treatment with BCG for urothelial carcinoma. The woman had received intravesical BCG therapy for urothelial carcinoma and was later found to have asymptomatic right kidney masses. She underwent surgery to remove the affected kidney and was diagnosed with BCG-induced kidney granulomas. After receiving treatment with corticosteroids and antimycobacterial agents, her condition improved, and she was discharged in good health. [Extracted from the article]

A case report in the journal "Reactions Weekly" describes a patient who developed a granuloma as a result of polytetrafluoroethylene used in microvascular decompression for trigeminal neuralgia. Two years after the initial procedure, the patient experienced recurrent symptoms, leading to the discovery of the granuloma through brain imaging. The patient underwent surgical excision of the granuloma to address the issue. [Extracted from the article]

A 49-year-old woman developed a sarcoidosis-like reaction in the oral mucosa while being treated with adalimumab for Crohn's disease. The woman had a 2-month long ulcerated swelling in the left lower fornix, and histological analysis revealed non-caseating granulomas and multinucleated cells. She received unspecified corticosteroid treatment, and the lesion is now under control, with monitoring for any further manifestations in other organs and systems. [Extracted from the article]

A 69-year-old woman developed erythema induratum of bazin, a skin condition, while being treated with dupilumab for atopic dermatitis. She initially had erythematous plaques and itchy nodules on her limbs and trunk, and had previously tried other medications without success. After starting treatment with dupilumab, her symptoms improved, but after 10 weeks she developed firm subcutaneous nodules. Biopsy results showed fat necrosis and granulomas, and a tuberculosis test was positive. It was determined that the woman developed erythema induratum of bazin as a result of the dupilumab treatment. The treatment was discontinued, but her atopic dermatitis continued to improve. [Extracted from the article]

A 39-year-old woman developed sarcoidal tattoo granulomata after receiving the elasomeran vaccine for COVID-19. She presented with a pruritic rash on her tattoos, which appeared about a month after receiving the second dose of the vaccine. Biopsy results showed a sarcoid-like cutaneous reaction to tattoo pigment. The woman was treated with hydrocortisone and clobetasol, but only saw minimal improvement. However, after being treated with prednisone, her symptoms significantly improved. [Extracted from the article]

A 58-year-old woman developed mucosal pyogenic granuloma (PG) while being treated with rituximab for pemphigus vulgaris. She presented with a bleeding lesion on her upper lip mucosa that had been growing for 2 months. The lesion was excised and diagnosed as mucosal PG through histopathological examination. The woman did not receive rituximab treatment again and was given dapsone therapy, with no relapse of PG during a 2-year follow-up. The mucosal PG was considered to be related to rituximab. [Extracted from the article]

A 58-year-old woman developed mucosal pyogenic granuloma (PG) while being treated with rituximab for pemphigus vulgaris. She presented with a bleeding lesion on her upper lip mucosa that had been growing for 2 months. The lesion was excised and diagnosed as mucosal PG through histopathological examination. The woman did not receive rituximab treatment again and was given dapsone therapy, with no relapse of PG during a 2-year follow-up. The mucosal PG was considered to be related to rituximab. [Extracted from the article]

A 57-year-old woman developed foreign body granuloma after receiving a dermal filler injection of polymethylmethacrylate. She also experienced a lack of efficacy from the COVID-19 vaccine, as she tested positive for COVID-19 despite receiving a booster dose. The woman received treatment with steroids and fluorouracil for the granulomas, which resulted in mild improvement. Histology confirmed the presence of foreign body granuloma secondary to polymethylmethacrylate, and further treatment led to improvement. [Extracted from the article]

A man in his 30s developed granulomas at the injection site after intentionally misusing mineral-oil injections. Prior to this, he had also misused testosterone. The granulomas were a result of a foreign body reaction. The man experienced symptoms such as nausea, dizziness, and discomfort, and was later diagnosed with acute kidney failure and severe hypercalcemia. Despite treatment with prednisolone, his calcium levels continued to rise, leading to end-stage renal disease and the need for dialysis. After 8 years of mineral-oil misuse, the man experienced cardiac arrest and died. Autopsy findings revealed widespread calcifications in multiple organs, with the cause of death attributed to extensive calcium-phosphate deposits in the heart. [Extracted from the article]

A 67-year-old man developed bone marrow granuloma after self-administering amiodarone without proper cardiology supervision. Despite receiving iron and vitamin supplements, the man had persistent pancytopenia. Various tests were conducted to rule out other causes, including tick-borne diseases, infections, and malignancy. It was discovered that the patient had been taking amiodarone without appropriate supervision, leading to the diagnosis of amiodarone-induced bone marrow granuloma. The medication was stopped, and the patient received sotalol, resulting in an improvement in his condition. [Extracted from the article]

A 31-year-old woman developed foreign body granuloma after receiving progesterone injections during the first trimester of her pregnancy. She presented with bilateral buttock masses and pain that lasted for over a year. Ultrasound examinations revealed increased echoes and panniculitis with local liquefaction changes. The woman underwent surgery to remove the masses and showed good recovery after the procedure. The foreign body granuloma was attributed to the exposure of progesterone. [Extracted from the article]

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is:• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventA 54-year-old man developed Majocchi's granuloma during treatment with econazole/triamcinolone and betamethasone/fusidic acid for pruritic rash [dosages and duration of treatment to reaction onset not stated]. [Extracted from the article]

A retrospective study conducted in Taiwan between July 2019 and July 2020 examined 10 patients with stage IV non-small cell lung cancer (NSCLC) who developed paronychia or pseudopyogenic granuloma while being treated with afatinib, erlotinib, osimertinib, or gefitinib. The patients also did not respond to treatment with timolol, neomycin, and tyrothricin for these conditions. However, when the patients were treated with 0.5% topical timolol solution, neomycin, and tyrothricin ointment, six patients showed improvement and all patients eventually experienced complete resolution of their paronychia and pseudopyogenic granuloma. [Extracted from the article]

In a retrospective study involving 41,775 patients, 37 individuals (34 women and 3 men) between the ages of 23 and 74 developed various complications after receiving hyaluronic acid filler treatment. These complications included vascular compromise, infection, allergy, neuropathy, acute conjunctivitis, late-onset allergy, and granuloma. The patients received different types of hyaluronic acid fillers in various areas of the face. Treatment for the complications included medications such as hyaluronidase, antibiotics, corticosteroids, and antihistamines. Most of the complications resolved or improved, but one patient was lost to follow-up. [Extracted from the article]

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is:• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventAn 8.9-year-old girl experienced granuloma formation and sterile abscess at injection site following treatment with leuprorelin and triptorelin for central precocious puberty. Additionally, she exhibited lack of efficacy following treatment with leuprorelin for central precocious puberty [routes and outcomes not stated; not all dosages and times to reactions onsets stated]. [Extracted from the article]

A 62-year-old woman developed reactive capillary haemangioma (RCH) and pyogenic granuloma while being treated with camrelizumab for liver cancer. She had been receiving camrelizumab injections every three weeks for six months, along with regorafenib. She presented with multiple skin lesions on her abdomen and a mass in her gums. The lesions grew rapidly and affected her food intake. She was diagnosed with RCH and pyogenic granuloma due to camrelizumab and underwent treatment, but her mental state became intolerable due to continuous skin lesion formation, leading to the suspension of camrelizumab therapy. [Extracted from the article]

Conventional radiography revealed a bone-condensation reaction with a periosteal reaction close to the ulcers; CT scan showed subcutaneous fat tissues and muscle compartments filled with nodules, where severe muscle oedema was evident. The left leg ulcer worsened after use of different wound dressings and negative pressure wound therapy; however, it was healed by venous compression. Therefore, the patient's right leg ulcer was treated with negative pressure wound therapy with resolution. [Extracted from the article]

The woman, who had early-onset Vogt-Koyanagi-Harada (VKH) disease, had been receiving azathioprine and unspecified oral steroids. The treatment with azathioprine was stopped, and the woman started receiving anti-tubercular therapy (Category II of DOTS; for extra-pulmonary tuberculosis) along with unspecified oral steroids, which was gradually tapered over 3 months and stopped. Fundus fluorescein angiography (FFA) and Indo-cyanine angiography (ICG) revealed multiple active lesions at the level of choroid and retinal pigment epithelium (RPE). [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 21-year-old woman developed recurrent paradoxical reaction presented as recurrent granuloma during treatment with isoniazid, rifampin, pyrazinamide and ethambutol for tuberculosis (TB). Her anti-TB treatment was discontinued at the end of nine months despite recurrent complaints. [Extracted from the article]

An ultrasound scan showed massive silicon leakage from the left implant and silicone-filled lymph nodes. Postoperative PET/CT after two months showed partial regression of thoracic and axillary lymph nodes. An MRI mammography showed bilaterally cured implants and intracapsular rupture of the left-sided implant with silicon leakage and granular conversion below the fibrous capsule. [Extracted from the article]

One week after receiving the hyaluronic acid infusion, she developed painful erythema and induration at the infusion site. Thereafter, she developed erythema and induration with infiltration on the face, left upper arm and right thigh. The left upper arm was touched with induration 3cm in diameter and erythema with induration 5cm in diameter was noted on the outside of the right thigh. [Extracted from the article]

She had a history of gluteal IM estrogen injections but no history of other medications with a risk of granuloma formation or calcification. The clinical presentation and imaging findings supported the diagnosis of dystrophic calcification following granuloma formation in the setting of estrogen injections. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event In a report 3 patients [2 women and 1 man] aged 52-82 years were described, who developed pyogenic granuloma (PG) during treatment with ibrutinib for chronic lymphocytic leukaemia (CLL) or mantle cell leukaemia [ I routes not stated i ]. After 24 months of therapy, she developed PG on the intergluteal fold and on the right hallux nail confirmed by pathology. Following 11 months of therapy, he presented with fingertip and ungual lesion of the right hallux. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event An approximately 1-month-old girl developed perforating granuloma annulare following immunisation with BCG vaccine. A diagnosis of BCG vaccine-induced perforating granuloma annulare was considered. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event In a case report, two patients were described: A 57-year-old man developed Stevens Johnson syndrome during treatment with pembrolizumab for NSCLC-adenocarcinoma. A 63-year-old woman developed periungual granuloma during treatment with afatinib and itchy acneiform rash during treatment with gefitinib for poorly differentiated pulmonary adenocarcinoma [ I routes and dosages not stated; not all duration of treatments to reactions onset and outcomes stated i ]. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 6-year-old boy developed subcutaneous granuloma annulare (SGA) during treatment with acetazolamide for idiopathic intracranial hypertension (IIHT). The boy (at the age of 9 years), who had been receiving treatment with acetazolamide for IIHT [ I route and dosage not stated i ], presented with recurring subcutaneous nodules on both legs (current presentation). The acetazolamide therapy was stopped at that time because of metabolic acidosis and improvement of IIHT symptoms. [Extracted from the article]